Lovastatin CAS: 75330-75-5
MF: C24H36O5
MW: 404.54
A hypocholesterolemic HMGCR inhibitor (statin that lowers cholesterol levels).

Lovastatin (CAS 75330-75-5)

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 122ms
  • REVIEWS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
5
0
4
0
3
1
2
0
1
0
同義語 Mevacor;Monacolin K;mevinolin;6-α-Methylcompactin
アプリケーション: A hypocholesterolemic HMGCR inhibitor (statin that lowers cholesterol levels)
CAS 番号: 75330-75-5
Purity: ≥97%
Molecular Weight: 404.54
Molecular Formula: C24H36O5
* Refer to Certificate of Analysis for lot specific data (including water content).
この製品のレビューを提出し、15 CruzCreditsを受け取ります

Lovastatin is a statin natural product isolated from numerous sources including the Pleurotus ostreatus oyster mushroom, demonstrating hypocholesterolemic and antiproliferative properties. Lovastatin inhibits HMGCR (3-hydroxy-3-methylglutaryl coenzyme A reductase), blocking the enzyme-catalyzed transformation of 3-hydroxy-3-methylglutaryl CoA into mevalonate. The biosynthesis of cholesterol requires mevalonate as a building block and elimination of mevalonate generation subsequently interrupts cholesterol synthesis, leading to a reduction of circulating low-density lipoproteins. Lovastatin demonstrates arrest of the cell cycle at the G1 phase in bladder carcinoma T24 cells expressing activated p21ras oncoprotein - the posttranslational isoprenylation of the p21ras with mevalonate is crucial for translocation and membrane adhesion of the protein, and blockade of this modification by Lovastatin-induced depletion of cellular mevalonate leads to suspension of cell progress. The signaling activity of epidermal growth factor (EGF) and insulin-like growth factor (IGF-I) are similarly affected by impairment of mevalonate-dependent protein prenylation. Induction of apoptosis by Lovastatin in malignant mesothelioma cells is also ascribed to the inhibition of mevalonate synthesis and posttranslational protein modifications. Lovastatin is a substrate of CYP and Mdr-1.


参考文献

1. Alberts, A.W. 1988. Am. J. Cardiol. 62: 10J-15J. PMID: 3055919
2. Hancock, J.F., et al. 1989. Cell. 57: 1167-1177. PMID: 2661017
3. Mendola, C.E. and Backer, J.M. 1990. Cell Growth Differ. 1: 499-502. PMID: 2278880
4. Vincent, T.S., et al. 1991. Biochem. Biophys. Res. Commun. 180: 1284-1289. PMID: 1953779
5. Jakóbisiak, M., et al. 1991. Proc. Natl. Acad. Sci. U.S.A. 88: 3628-3632. PMID: 1673788
6. Rubins, J.B., et al. 1998. Am. J. Respir. Crit. Care Med. 157: 1616-1622. PMID: 9603146
7. Bobek, P., et al. 1998. Nutrition. 14: 282-286. PMID: 9583372
8. Kim, W.S., et al. 2001. Invest New Drugs. 19: 81-83. PMID: 11291836

Physical State :
Solid
Derived From :
Non-native source; synthetic
Solubility :
Soluble in DMSO (10 mg/ml), ethanol (10 mg/ml), methanol, chloroform, acetone, acetonitrile, DMF, and water (0.4 µg/ml).
保存方法 :
Store at -20° C
Melting Point :
175.4° C
Boiling Point :
~559.2° C at 760 mmHg (Predicted)
Density :
~1.1 g/cm3 (Predicted)
Refractive Index :
n20D 1.53
Optical Activity :
α20/D 320°±10°, c = 0.5 in CH3CN
IC50 :
HMG-CoA reductase: IC50 = 0.01 µM (rat); Inhibition of the incorporation of sodium [14C]acetate into cholesterol: IC50 = 0.05 µM (HEP G2 cells); inhibition of recombinant ICAM-1 binding to purified immobilized LFA-1: IC50 = 3.78 µM; CYP51: IC50 = 200 µM (human)
Ki Data :
HMG-CoA reductase: Ki= 0.6 nM
試験・研究用以外には使用しないでください。 臨床及び体外診断には使用できません。
WGK Germany :
3
RTECS :
EK7907000
PubChem CID :
53232
Merck Index :
14: 5586
MDL Number :
MFCD00072164

Download SDS (MSDS)

分析表

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

Lovastatin  参考文献

See how others have used Lovastatin. Click on the entry to view the PubMed entry .

Citations 1 to 7 of 7 total

PMID: # 27159577  Shimada, K. et al. 2016. Nature chemical biology. 12: 497-503.

PMID: # 26243146  Meunier, S. et al. 2015. Nature communications. 6: 7889.

PMID: # 10196184  Reimer, CL. et al. 1999. J. Biol. Chem. 274: 11022-11029.

PMID: # 10196184  Reimer, CL. et al. 1999. J. Biol. Chem. 274: 11022-11029.

PMID: # 9653194  De Petrocellis, L. et al. 1998. Proc. Natl. Acad. Sci. USA. 95: 8375-8380.

PMID: # 9341167  Vogt, A. et al. 1997. J. Biol. Chem. 272: 27224-27229.

PMID: # 9341167  Vogt, A. et al. 1997. J. Biol. Chem. 272: 27224-27229.

Citations 1 to 7 of 7 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 117ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 9ms
  • REVIEWS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;

サンタクルーズバイオテクノロジーは生物医学研究市場向けの製品の開発における世界的リーダです。 下記フリー ダイヤルにお電話ください: 1-800-457-3801。Copyright © 2007-2020 Santa Cruz Biotechnology, Inc.全著作権所有。"Santa Cruz Biotechnology"、 及びSanta Cruz Biotechnology, Inc. ロゴ、 "Santa Cruz Animal Health"、 "San Juan Ranch"、 "Supplement of Champions"、 San Juan Ranch ロゴ、 "Ultracruz"、 "Chemcruz"、 "Immunocruz"、 "Exactacruz"、 と "EZ Touch"はサンタクルーズバイオテクノロジーの登録商標です。 商標はそれぞれの所有者に帰属します。